Know the Latest About COVID-19 Monoclonal Antibodies
Recent evidence and rising cases will renew focus on COVID-19 monoclonal antibodies...casirivimab/imdevimab (Regen-COV), etc.
Patients. Early data now suggest casirivimab/imdevimab reduces mortality in patients HOSPITALIZED due to COVID-19.
But it's not authorized for these patients yet...and the dose showing benefit is over 6 times the current authorized dose.